WB
Therapeutic Areas
Valneva SE Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IXCHIQ® (VLA1553) | Chikungunya virus disease (prevention) | Approved |
| IXIARO®/JESPECT® | Japanese Encephalitis (prevention) | Approved |
| VLA15 | Lyme Borreliosis (prevention) | Phase 3 |
| VLA1553 (Pediatric) | Chikungunya (prevention) in pediatric population | Phase 3 |
| VLA2111 | Chikungunya (prevention) | Phase 1 |
| VLA1601 | Zika virus disease (prevention) | Preclinical |
Leadership Team at Valneva SE
TL
Thomas Lingelbach
Chief Executive Officer (CEO) and Director of Valneva Austria GmbH
PB
Peter Bühler
Chief Financial Officer (CFO)
JC
Juan Carlos Jaramillo, M.D.
Chief Medical Officer (CMO)
FJ
Frédéric Jacotot
Executive Vice President, Corporate Strategy
FG
Franck Grimaud
Executive Vice President, Chief Business Officer
J(
James (Jim) F. Cummings
Executive Vice President, General Counsel
HB
Hervé Brailly, Ph.D.
Chairman of the Supervisory Board
MM
Muriel Marchand
Member of the Supervisory Board
S(
Svetlana (Lana) Skibo
Member of the Supervisory Board
YG
Yvonne Greenstreet, MBChB
Member of the Supervisory Board